For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria prior to Surgery:

          -  Suspected or histologically confirmed Stage IIA to IIIB NSCLC with disease that is
             considered resectable

          -  Must be deemed eligible for complete resection and must agree to undergo standard of
             care surgery for complete resection of NSCLC

          -  Treatment naive (no previous systemic treatment)

        Inclusion Criteria prior to Treatment Randomization:

          -  Must have undergone complete surgical resection of their Stage IIA to IIIB NSCLC

          -  Must have adequately recovered from surgery at the time of randomization

          -  Minimal residual disease (MRD) positive results as detected by ctDNA

        Exclusion Criteria prior to Surgery:

          -  Participants with known EGFR mutations which are sensitive to available targeted
             inhibitor therapy (Prior to treatment randomization in select sites)

          -  Active, known or suspected autoimmune disease

          -  Participants with a condition requiring systemic treatment with either corticosteroids
             (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of randomization

        Exclusion Criteria prior to Treatment Randomization:

          -  Must continue to meet Exclusion Criteria prior to Surgery

          -  Must have no evidence of metastatic disease after surgery

          -  Received a live/attenuated vaccine within 30 days of first treatment

        Other protocol defined inclusion/exclusion criteria could apply